Clinical Trial Update: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BMS-936558 (nivolumab) to physician's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy; trial completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Melanoma
• Unresectable Melanoma

Drugs mentioned

• BMS-936558
• CARBOPLATIN (Carboplatin)
• Dacarbazine (dacarbazine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Unresectable or Metastatic Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2017-03-22